A5080981511- Glioma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Calcium signaling and nucleotide metabolism
- Multiple Myeloma Research and Treatments
- Cancer therapeutics and mechanisms
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Epigenetics and DNA Methylation
- Cancer Research and Treatments
- Lymphoma Diagnosis and Treatment
- Ethics in Clinical Research
- Toxin Mechanisms and Immunotoxins
- Meningioma and schwannoma management
- Cancer, Hypoxia, and Metabolism
- Immunotherapy and Immune Responses
- Multiple and Secondary Primary Cancers
- Cancer Cells and Metastasis
- Esophageal Cancer Research and Treatment
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Histone Deacetylase Inhibitors Research
West Virginia University
2020-2024
Virginia Cancer Institute
2020-2021
Mayo Clinic in Florida
2017-2021
WinnMed
2018-2019
Jacksonville College
2018
Abstract With improving survivorship in chronic lymphocytic leukemia (CLL), the risk of second primary malignancies (SPMs) has not been systematically addressed. Differences for SPMs among CLL survivors from Surveillance, Epidemiology, and End Results (SEER) database (1973–2015) were compared to individual expected general population. In ~270,000 person-year follow-up, 6487 new diagnosed with a standardized incidence ratio (SIR) 1.2 (95% CI:1.17–1.23). The higher was both solid (SIR 1.15;...
CD38 has emerged as a high-impact therapeutic target in multiple myeloma, with the approval of daratumumab (anti-CD38 mAb). The clinical importance patients chronic lymphocytic leukemia (CLL) been known for over 2 decades, although it's relevance CLL remains understudied.We investigated biological effects and antitumor mechanisms engaged by primary cells. Besides its immune-effector (antibody-dependent cell-mediated cytotoxicity, complement-dependent death, antibody-dependent cellular...
Abstract Patients with chronic lymphocytic leukemia (CLL) are characterized by monoclonal expansion of CD5+CD23+CD27+CD19+κ/λ+ B lymphocytes and clinically noted to have profound immune suppression. In these patients, it has been recently shown that a subset cells possesses regulatory functions secretes high levels interleukin 10 (IL-10). Our investigation identified CLL CD19+CD24+CD38hi immunophenotype (B cell [Breg]–like cells) produce amounts IL-10 transforming growth factor β (TGF-β)...
Abstract Gliomas are the most prevalent neurological cancer in USA and care modalities not able to effectively combat these aggressive malignancies. Identifying new, more effective treatments require a deep understanding of complex genetic variations relevant pathway associations behind cancers. Drawing connections between gene mutations with responsive target can help drive therapy selections enhance patient survival. We have performed extensive molecular profiling Capicua ( CIC) , tumor...
The blood-brain barrier is the selectively permeable vasculature of brain vital for maintaining homeostasis and neurological function. Low permeability beneficial in presence toxins pathogens blood. However, metastatic tumors, it a challenge drug delivery. Although blood-tumor slightly leaky, still not permissive enough to allow accumulation therapeutic concentrations metastases. Herein, we discuss differences between primary tumors vasculature, effects therapeutics on barrier,...
Standard-of-care first-line therapy for patients with newly diagnosed glioblastoma (ndGBM) is maximal safe surgical resection, then concurrent radiotherapy and temozolomide, followed by maintenance temozolomide. IGV-001, the first product of Goldspire™ platform, a first-in-class autologous immunotherapeutic that combines personalized whole tumor–derived cells an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers, intent to induce tumor-specific immune response ndGBM....
Concern exists that the clinical trial populations differ from respective cancer in terms of their age distribution affecting generalizability results, especially underrepresented minorities. We hypothesized trials do not report race are likely to suffer a higher degree disparity.Food and Drug Administration (FDA) drug approvals July 2007 June 2019 were reviewed identify oncology approvals, with details selected. The outcomes studied weighted mean difference between population real-world for...
Summary CD38 is expressed on Waldenström macroglobulinaemia (WM) cells, but its role as a therapeutic target remains undefined. With recent approval of the anti‐CD38 monoclonal antibody, daratumumab (Dara), we hypothesized that blocking would be lethal to WM cells. In vitro Dara treatment cells (including ibrutinib‐resistant lines) elicited antibody‐dependent cellular cytotoxicity (ADCC), complement‐dependent (CDC), cell phagocytosis (ADCP) and direct apoptosis. vivo , was well tolerated...
e14030 Background: Glioblastoma (GBM) is the primary malignant tumor of brain with a dismal outcome. Current management includes maximal safe surgical resection, radiation therapy concomitant and adjuvant temozolomide (TMZ). Its recurrence inevitable limited available therapies. In era targeted therapeutics, CD38 can be potential target especially availability Daratumumab; an FDA approved Anti-CD38 monoclonal antibody. expressed on 25% tumor-microglia macrophages that form 40% bulk glioma....
Intracranial metastasis is a rare sequela of esophageal adenocarcinoma (EAC), typically presenting within the first 2 years after primary tumor detection. Our patient 72-year-old man diagnosed with an EAC in 2015 and presented recurrence distant solitary brain lesion approximately 6 initial diagnosis. Histological diagnosis was confirmed as all relevant indicators. In addition, we used genomic profiling to detect biomarkers that can be useful future for therapies.
Abstract BACKGROUND Insights into the pathogenesis of diffuse hemispheric glioma, H3 G34-mutant (DHG-G34), an incurable high-grade have opened new therapeutic possibilities. The DHG-G34 oncohistone mutation impairs epigenetic regulator SETD2, which normally orchestrates DNA-mismatch-repair and negatively regulates Polycomb Repressive Complex 2 (PRC2). In DHG-G34, a mismatch-repair-deficiency phenotype is predicted, but anti-tumor immune response notably absent, we hypothesize linked to...
e14034 Background: In cancers of the nervous system such as neuroblastoma (NB), ubiquitin ligase UBE4B directly ubiquitinates growth factor receptors (GFRs), influencing their trafficking and lysosomal degradation. While diverse functions are acknowledged, we hypothesize that expression has distinct associations with outcomes in pediatric versus adult cancers. We examined impact on glioblastoma (GBM) development, growth, metastasis by correlating its patient across age groups. Methods:...
Abstract Background High-grade gliomas (HGGs) are the most aggressive type of and have poorest outcomes. Chromatin remodeling (CR) genes been implicated in multiple oncogenic pathways numerous cancer types. In gliomagenesis, CR regulating stemness glioma cells, tumor microenvironment (TME), resistance to therapies. Methods We performed molecular profiling 4244 HGGs evaluated associations mutations with other cancer-related biomarkers, infiltration by immune gene expression. also association...
2082 Background: Recent insights into the molecular basis of diffuse hemispheric glioma, H3 G34-mutant (DHG-G34), an incurable high-grade have opened new therapeutic possibilities. The oncohistone mutation in DHG-G34 impairs epigenetic regulator SETD2, which normally orchestrates DNA-mismatch-repair and negatively regulates transcriptional silencing activity Polycomb Repressive Complex 2 (PRC2). In DHG-G34, a mismatch-repair-deficiency phenotype is predicted, but anti-tumor immune response...